Scholarlink

<p>At present, the role of Cysteine and glycine rich protein 1 (CSRP1) in the occurrence and development of diffuse large B lymphoma (DLBCL) has not been reported. We conducted a comprehensive analysis of the potential value of CSRP1 in DLBCL using multiple independent datasets and analytical methods, including differential expression analysis, pathway analysis and immune analysis. Then, cell experiments were used to confirm the regulatory role of CSRP1 in DLBCL. The analysis results show that in DLBCL patients, the expression of CSRP1 is significantly upregulated. In addition, CSRP1 is associated with the cell cycle related pathways and immune microenvironment in DLBCL. Cell experiments confirmed that CSRP1 can significantly regulate the apoptosis and cycle progression of DLBCL cells. In conclusion, CSRP1 may be a potential therapeutic target for DLBCL patients, our research provides a theoretical basis for improving the clinical treatment of DLBCL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月16日

查看全文
  • Wanlu Tian,
  • Fengbo Jin,
  • Yingying Chen,
  • Mingzhen Yang

摘要

At present, the role of Cysteine and glycine rich protein 1 (CSRP1) in the occurrence and development of diffuse large B lymphoma (DLBCL) has not been reported. We conducted a comprehensive analysis of the potential value of CSRP1 in DLBCL using multiple independent datasets and analytical methods, including differential expression analysis, pathway analysis and immune analysis. Then, cell experiments were used to confirm the regulatory role of CSRP1 in DLBCL. The analysis results show that in DLBCL patients, the expression of CSRP1 is significantly upregulated. In addition, CSRP1 is associated with the cell cycle related pathways and immune microenvironment in DLBCL. Cell experiments confirmed that CSRP1 can significantly regulate the apoptosis and cycle progression of DLBCL cells. In conclusion, CSRP1 may be a potential therapeutic target for DLBCL patients, our research provides a theoretical basis for improving the clinical treatment of DLBCL.